Radiation oncology firm Accuray is highlighting research presented at the recent European Society for Radiotherapy and Oncology annual congress (ESTRO) on the benefits of its CyberKnife robotic radiotherapy platform in prostate cancer treatment.
Results from the Prostate Advances in Comparative Evidence (PACE) prospective, randomized, and international multicenter study showed that two years after treatment, patients treated with CyberKnife stereotactic body radiation therapy (SBRT) experienced bladder side effects half as often as those who were treated using conventional linear accelerators.
The study was presented at ESTRO 2021 by Dr. Alison Tree, a consultant clinical oncologist at the Royal Marsden NHS Foundation Trust and leader of the Uro-Oncology Clinical Trials team at the Institute of Cancer Research, according to Accuray.
